[1] Ohmi M, Tabayashi K, Tsuru Y, et al. Result of surgical treatment of true or dissected thoracic aneurysm: determinants analysis in operative mortality and morbidity[J]. Kyobu Geka, 1992, 45(9): 773-779. [2] 孙立忠, 常谦, 胡晓鹏, 等. 一期次全或全主动脉替换术的临床应用[J]. 中华外科杂志, 2005, 43(22): 1425-1428. [3] Veldman A, Hoffman M, Ehrenforth S. New insights into the coagulation system and implications for new therapeutic options with recombinant factor Ⅶa [J]. Curr Med Chem, 2003, 10(10): 797-811. [4] Jarosz K, Czuprynska M, Andrzejewska J, et al. Administration of a recombinant factor Ⅶa in patients undergoing liver transplantation for fulminant hepatic failure[J]. Transplant Proc, 2009, 41(8): 3088-3090. [5] Magon N, Babu K. Recombinant factor Ⅶa in post-partum hemorrhage: A new weapon in obstetrician's armamentarium[J]. N Am J Med Sci, 2012, 4(4): 157-162. [6] Elizalde M, Slobodskoy L, Diodato M, et al. Use of recombinant factor Ⅶ in cardiac surgery[J]. Recent Pat Cardiovasc Drug Discov, 2012, 7(3): 216-220. [7] Mittal S, Watson HG. A critical appraisal of the use of recombinant factor Ⅶa in acquired bleeding conditions[J]. Br J Haematol, 2006, 133(4): 355-363. [8] Chapman AJ, Blount AL, Davis AT, et al. Recombinant factor Ⅶa (NovoSeven RT) use in high risk cardiac surgery [J]. Eur J Cardiothorac Surg, 2011, 40(6): 1314-1318. |